Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Condensed Consolidated Statements of Operations
Net Revenues	$ 48,470	$ 54,357	$ 98,244	$ 107,244
Operating Expenses:
Cost of sales (excluding depreciation and amortization)	20,695	15,632	42,499	30,357
Research and development	3,035	5,773	9,379	10,146
Selling, general, and administrative	21,213	14,188	34,896	27,472
Depreciation and amortization	11,198	9,472	22,381	25,575
Cortrophin pre-launch charges	3,636		8,238	0
Total Operating Expenses	59,777	45,065	117,393	93,550
Operating (Loss)/Income	(11,307)	9,292	(19,149)	13,694
Other Expense, net
Interest expense, net	(2,356)	(3,406)	(4,388)	(6,760)
Other income /(expense), net	(116)	46	(106)	(84)
(Loss)/Income Before Benefit/(Provision) for Income Taxes	(13,779)	5,932	(23,643)	6,850
Benefit for income taxes	1,443	653	4,296	184
Net (Loss)/Income	$ (12,336)	$ 6,585	$ (19,347)	$ 7,034
Basic and Diluted (Loss)/Earnings Per Share:
Basic (Loss)/Earnings Per Share	$ (1.03)	$ 0.55	$ (1.62)	$ 0.59
Diluted (Loss)/Earnings Per Share	$ (1.03)	$ 0.53	$ (1.62)	$ 0.57
Basic Weighted-Average Shares Outstanding	11,967	11,851	11,935	11,799
Diluted Weighted-Average Shares Outstanding	11,967	12,269	11,935	12,046